[email protected]

Login

Papers

Inflammatory Bowel Diseases, izab042.
Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases.

Inflammatory Bowel Diseases, izab143.
Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study.

Clin Gastroenterol Hepatol . 2021 Nov 26; S1542-3565(21)01268-4
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial

United European Gastroenterol J., 2021;9:1136–1147
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study

The American Journal of Human Genetics 92, 1008-1012, June 6, 2013
Large Sample Size, Wide Variant Spectrum, and Advanced Machine-Learning Technique Boost Risk Prediction for Inflammatory Bowel Disease

Nature genetics, MARCH 2011, VOLUME 43, NUMBER 3
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

Nature Genetics, AUGUST 2008, VOLUME 40, NUMBER 8
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

Nature Genetics, January 2009, Volume 41, Number 1
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility

‹
1
2
3
4
5
6
7
›